

Chronic Heart Failure Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/CA20EB3AE5E1EN.html>

Date: May 2024

Pages: 130

Price: US\$ 6,499.00 (Single User License)

ID: CA20EB3AE5E1EN

Abstracts

The 7 major chronic heart failure markets reached a value of US\$ 6.6 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 18.5 Billion by 2034, exhibiting a growth rate (CAGR) of 9.78% during 2024-2034.

The chronic heart failure market has been comprehensively analyzed in IMARC's new report titled "Chronic Heart Failure Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic heart failure (CHF), also known as congestive heart failure, is a progressive condition in which the heart is unable to pump enough blood to meet the body's needs. Some of the common symptoms indicative of the ailment are irregular heartbeat, fatigue, shortness of breath, chest pain, nausea, swelling in the legs, ankles, and feet, coughing, etc. The diagnosis of chronic heart failure typically involves a comprehensive evaluation that includes a medical history, physical examination, and various tests. The physical examination is performed to measure the vital signs and evaluate the heart and lung functions. Some of the laboratory investigations used to diagnose CHF include blood tests, electrocardiogram (ECG), chest X-ray, echocardiogram, and cardiac catheterization. Blood tests are carried out to identify any underlying health problems that may contribute to heart failure, such as anemia or kidney problems. Additionally, an ECG can help detect abnormalities in the heart's electrical activity, while an echocardiogram provides a detailed view of the heart's structure and function.

The increasing prevalence of coronary artery ailments and heart valve disorders is primarily driving the chronic heart failure market. In addition to this, the rising incidence of several CHF-associated prominent co-morbidities, such as obesity, diabetes, pulmonary diseases, hypertension, etc., is creating a positive outlook for the market.

Furthermore, the expanding geriatric population, who are more susceptible to developing cardiovascular diseases, is also bolstering the market growth. Apart from this, the widespread adoption of device-based therapies, including cardiac resynchronization therapy (CRT) and implantable cardioverter-defibrillators (ICDs), which utilize implantable devices to improve the heart's pumping function, is acting as a significant growth-inducing factor. Moreover, the increasing utilization of medications, such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), to reduce fluid buildup and relieve symptoms of chronic heart failure, including shortness of breath and fatigue, is further propelling the market. Additionally, several technological advancements, such as the introduction of cardiac mapping devices for identifying the cause of CHF, such as arrhythmias, structural heart defects, or ischemia, are also expected to drive the chronic heart failure market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the chronic heart failure market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for chronic heart failure and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic heart failure market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the chronic heart failure market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the chronic heart failure market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current chronic heart failure marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the chronic heart failure market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the chronic heart failure market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the chronic heart failure market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of chronic heart failure across the seven major markets?

What is the number of prevalent cases (2018-2034) of chronic heart failure by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of chronic heart failure by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with chronic heart failure across the seven major markets?

What is the size of the chronic heart failure patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of chronic heart failure?

What will be the growth rate of patients across the seven major markets?

Chronic Heart Failure: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for chronic heart failure drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic heart failure market?

What are the key regulatory events related to the chronic heart failure market?

What is the structure of clinical trial landscape by status related to the chronic heart failure market?

What is the structure of clinical trial landscape by phase related to the chronic heart failure market?

What is the structure of clinical trial landscape by route of administration related to the chronic heart failure market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 CHRONIC HEART FAILURE - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 CHRONIC HEART FAILURE - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 CHRONIC HEART FAILURE - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (?2018-2023?)
 - 7.2.2 Epidemiology Forecast (?2024-2034?)
 - 7.2.3 Epidemiology by Age (?2018-2034?)
 - 7.2.4 Epidemiology by Gender (?2018-2034?)
 - 7.2.5 Diagnosed Cases (?2018-2034?)
 - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (?2018-2023?)
 - 7.3.2 Epidemiology Forecast (?2024-2034?)
 - 7.3.3 Epidemiology by Age (?2018-2034?)
 - 7.3.4 Epidemiology by Gender (?2018-2034?)
 - 7.3.5 Diagnosed Cases (?2018-2034?)
 - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (?2018-2023?)
 - 7.4.2 Epidemiology Forecast (?2024-2034?)
 - 7.4.3 Epidemiology by Age (?2018-2034?)
 - 7.4.4 Epidemiology by Gender (?2018-2034?)
 - 7.4.5 Diagnosed Cases (?2018-2034?)
 - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (?2018-2023?)
 - 7.5.2 Epidemiology Forecast (?2024-2034?)
 - 7.5.3 Epidemiology by Age (?2018-2034?)
 - 7.5.4 Epidemiology by Gender (?2018-2034?)
 - 7.5.5 Diagnosed Cases (?2018-2034?)
 - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (?2018-2023?)
 - 7.6.2 Epidemiology Forecast (?2024-2034?)
 - 7.6.3 Epidemiology by Age (?2018-2034?)
 - 7.6.4 Epidemiology by Gender (?2018-2034?)
 - 7.6.5 Diagnosed Cases (?2018-2034?)
 - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (?2018-2023?)
 - 7.7.2 Epidemiology Forecast (?2024-2034?)
 - 7.7.3 Epidemiology by Age (?2018-2034?)

- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (?2018-2023?)
 - 7.8.2 Epidemiology Forecast (?2024-2034?)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Diagnosed Cases (?2018-2034?)
 - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (?2018-2023?)
 - 7.9.2 Epidemiology Forecast (?2024-2034?)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Diagnosed Cases (?2018-2034?)
 - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

8 CHRONIC HEART FAILURE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 CHRONIC HEART FAILURE - UNMET NEEDS

10 CHRONIC HEART FAILURE - KEY ENDPOINTS OF TREATMENT

11 CHRONIC HEART FAILURE - MARKETED PRODUCTS

- 11.1 List of Chronic Heart Failure Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Verquvo (Vericiguat) - Bayer HealthCare Pharmaceuticals/Merck & Co
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets
 - 11.1.2 Entresto (Sacubitril/valsartan) - Novartis
 - 11.1.2.1 Drug Overview

- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets
- 11.1.3 Corlanor (Ivabradine) - Servier
 - 11.1.3.1 Drug Overview
 - 11.1.3.2 Mechanism of Action
 - 11.1.3.3 Regulatory Status
 - 11.1.3.4 Clinical Trial Results
 - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Farxiga (Dapagliflozin) - AstraZeneca
 - 11.1.4.1 Drug Overview
 - 11.1.4.2 Mechanism of Action
 - 11.1.4.3 Regulatory Status
 - 11.1.4.4 Clinical Trial Results
 - 11.1.4.5 Sales Across Major Markets
- 11.1.5 Jardiance (Empagliflozin) - Boehringer Ingelheim/Eli Lilly and Company
 - 11.1.5.1 Drug Overview
 - 11.1.5.2 Mechanism of Action
 - 11.1.5.3 Regulatory Status
 - 11.1.5.4 Clinical Trial Results
 - 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 CHRONIC HEART FAILURE - PIPELINE DRUGS

- 12.1 List of Chronic Heart Failure Pipeline Drugs Across the Top 7 Markets
 - 12.1.1 IONISAGT LRx - Ionis Pharmaceuticals
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status
 - 12.1.2 Finerenone - Bayer HealthCare Pharmaceuticals
 - 12.1.2.1 Drug Overview
 - 12.1.2.2 Mechanism of Action
 - 12.1.2.3 Clinical Trial Results
 - 12.1.2.4 Safety and Efficacy

- 12.1.2.5 Regulatory Status
- 12.1.3 Omecamtiv mecarbil - Cytokinetics
 - 12.1.3.1 Drug Overview
 - 12.1.3.2 Mechanism of Action
 - 12.1.3.3 Clinical Trial Results
 - 12.1.3.4 Safety and Efficacy
 - 12.1.3.5 Regulatory Status
- 12.1.4 Neucardin - Zensun (Shanghai) Sci & Tech
 - 12.1.4.1 Drug Overview
 - 12.1.4.2 Mechanism of Action
 - 12.1.4.3 Clinical Trial Results
 - 12.1.4.4 Safety and Efficacy
 - 12.1.4.5 Regulatory Status
- 12.1.5 AZD 4831 - AstraZeneca
 - 12.1.5.1 Drug Overview
 - 12.1.5.2 Mechanism of Action
 - 12.1.5.3 Clinical Trial Results
 - 12.1.5.4 Safety and Efficacy
 - 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. CHRONIC HEART FAILURE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. CHRONIC HEART FAILURE – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 CHRONIC HEART FAILURE - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
 - 15.2.1 Chronic Heart Failure - Market Size
 - 15.2.1.1 Market Size (?2018-2023?)
 - 15.2.1.2 Market Forecast (?2024-2034?)

- 15.2.2 Chronic Heart Failure - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (?2018-2023?)
 - 15.2.2.2 Market Forecast by Therapies (?2024-2034?)
- 15.3 Market Scenario - United States
 - 15.3.1 Chronic Heart Failure - Market Size
 - 15.3.1.1 Market Size (?2018-2023?)
 - 15.3.1.2 Market Forecast (?2024-2034?)
 - 15.3.2 Chronic Heart Failure - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (?2018-2023?)
 - 15.3.2.2 Market Forecast by Therapies (?2024-2034?)
 - 15.3.3 Chronic Heart Failure - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Chronic Heart Failure - Market Size
 - 15.4.1.1 Market Size (?2018-2023?)
 - 15.4.1.2 Market Forecast (?2024-2034?)
 - 15.4.2 Chronic Heart Failure - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (?2018-2023?)
 - 15.4.2.2 Market Forecast by Therapies (?2024-2034?)
 - 15.4.3 Chronic Heart Failure - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Chronic Heart Failure - Market Size
 - 15.5.1.1 Market Size (?2018-2023?)
 - 15.5.1.2 Market Forecast (?2024-2034?)
 - 15.5.2 Chronic Heart Failure - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (?2018-2023?)
 - 15.5.2.2 Market Forecast by Therapies (?2024-2034?)
 - 15.5.3 Chronic Heart Failure - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Chronic Heart Failure - Market Size
 - 15.6.1.1 Market Size (?2018-2023?)
 - 15.6.1.2 Market Forecast (?2024-2034?)
 - 15.6.2 Chronic Heart Failure - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (?2018-2023?)
 - 15.6.2.2 Market Forecast by Therapies (?2024-2034?)
 - 15.6.3 Chronic Heart Failure - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Chronic Heart Failure - Market Size
 - 15.7.1.1 Market Size (?2018-2023?)
 - 15.7.1.2 Market Forecast (?2024-2034?)

- 15.7.2 Chronic Heart Failure - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (?2018-2023?)
 - 15.7.2.2 Market Forecast by Therapies (?2024-2034?)
- 15.7.3 Chronic Heart Failure - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Chronic Heart Failure - Market Size
 - 15.8.1.1 Market Size (?2018-2023?)
 - 15.8.1.2 Market Forecast (?2024-2034?)
 - 15.8.2 Chronic Heart Failure - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (?2018-2023?)
 - 15.8.2.2 Market Forecast by Therapies (?2024-2034?)
 - 15.8.3 Chronic Heart Failure - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Chronic Heart Failure - Market Size
 - 15.9.1.1 Market Size (?2018-2023?)
 - 15.9.1.2 Market Forecast (?2024-2034?)
 - 15.9.2 Chronic Heart Failure - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (?2018-2023?)
 - 15.9.2.2 Market Forecast by Therapies (?2024-2034?)
 - 15.9.3 Chronic Heart Failure - Access and Reimbursement Overview

16 CHRONIC HEART FAILURE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 CHRONIC HEART FAILURE MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 CHRONIC HEART FAILURE MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Chronic Heart Failure Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/CA20EB3AE5E1EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CA20EB3AE5E1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

